無料プレビュー

Neurocrine Biosciences, Inc. (NBIX) · NASDAQ Global Select

プロフィール

Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company discovering, developing, and commercializing treatments for neurological, psychiatric, endocrine, and immunological disorders. The company markets FDA-approved products INGREZZA (valbenazine) for tardive dyskinesia and Huntington's disease chorea, and CRENESSITY (crinecerfont) for congenital adrenal hyperplasia, with a co-developed endometriosis/uterine fibroid treatment via AbbVie. The company operates through a specialized U.S. sales force of approximately 600 professionals targeting neurology, psychiatry, long-term c

主要指標

株価: $141.25 (-1.55%)
時価総額: 142億ドル
PER（今期予想）: 20.0
PBR: 3.9
配当利回り: —
52週レンジ: $122.14 – $186.12
業種: Healthcare / Biotechnology
上場: NASDAQ Global Select
構成銘柄: —

比較会社: VRTX Vertex Pharmaceuticals Incorporated、MRNA Moderna, Inc.、REGN Regeneron Pharmaceuticals, Inc.、ARGX argenx SE、SGEN Seagen Inc.、RVMD Revolution Medicines, Inc.、ONC BeOne Medicines AG、ALNY Alnylam Pharmaceuticals, Inc.

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2026-10-27 · 更新: 2026-10-09